Shares of Akari Therapeutics (AKTS) rocketed higher in premarket trading on Friday, more than doubling from Thursday's close, after the biotech firm reported encouraging preclinical data for its lead cancer drug candidate and secured a $5.5 million private placement. The stock was indicated at $10.15, up from a $5.14 close, reflecting investor enthusiasm for the company's pipeline progress.
Preclinical Data Drives Momentum
Akari announced that its antibody-drug conjugate (ADC), AKTX-101, demonstrated synergistic cell-killing activity when combined with adagrasib, a KRAS inhibitor, in pancreatic cancer cell lines harboring KRAS G12D and G12C mutations. KRAS is a key gene involved in cell growth regulation, and its mutated forms are notoriously difficult to target, particularly in pancreatic, colorectal, and non-small cell lung cancers.
The company highlighted that this combination effect was not observed with comparator TROP2 ADCs using topoisomerase I inhibitor payloads, which instead showed antagonism when paired with adagrasib. This differentiation is critical, as it suggests Akari's PH1 payload may offer a fundamentally distinct mechanism of action compared to established TROP2-directed therapies.
Financial Boost and Cash Position
Alongside the data release, Akari announced a $5.5 million private placement, selling approximately 1.47 million American depositary shares (or pre-funded warrants) along with series H, I, and J warrants at $3.74 per ADS. The financing is expected to close in three tranches between May 27 and July 15. CEO Abizer Gaslightwala stated that the investment reflects "deep conviction" from long-term strategic investors.
The capital infusion is timely, as the company reported only $2.8 million in cash as of March 31, with an accumulated deficit of $279.0 million. In its recent quarterly filing, Akari noted that its cash was insufficient to fund operations for the next twelve months, raising "substantial doubt" about its ability to continue as a going concern. The new funds are earmarked for working capital and advancing AKTX-101 toward Phase 1 trials.
Clinical Timeline and Competitive Landscape
Akari has initiated IND-enabling studies and targets the start of a Phase 1 first-in-human trial by mid-2027. Phase 1 trials primarily assess safety and dosing in humans. The company reported a net loss of $14.5 million for the first quarter, compared to $3.7 million a year earlier, and has yet to generate any revenue.
The TROP2 ADC space is increasingly competitive, with Gilead's Trodelvy and AstraZeneca/Daiichi Sankyo's Datroway already approved for certain cancers. Akari's ability to carve out a niche with its PH1 payload could be significant, but the data remain preclinical, and lab results often fail to translate into human benefit.
Market Context and Risks
The sharp move in Akari's stock, while impressive, comes in a thinly traded biotech name, and gains could reverse quickly due to dilution from the new shares and warrants, clinical timing uncertainties, or the company's ongoing need for additional capital. With Nasdaq's regular session opening at 9:30 a.m. Eastern and a long Memorial Day weekend ahead, liquidity may be thin, adding to volatility.
Investors will be closely watching for further updates as Akari progresses toward human trials and seeks to validate its approach in one of the toughest oncology targets.
